Moderna to charge $25-$37 for COVID-19 vaccine: CEO
The EU has been in talks with Moderna for its experimental COVID-19 vaccine at least since July.
Moderna is all set to charge governments between $25 and $37 per dose of its Covid-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told a German weekly news outlet.
Speaking to Welt am Sonntag (WamS), he said: "Our vaccine, therefore, costs about the same as a flu shot, which is between $10 and $50.”
On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose.
“Nothing is signed yet, but we’re close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks,” Bancel told WamS, adding it was just a “matter of days” until a contract would be ready.
Moderna has said its experimental vaccine is 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial, becoming the second developer to report results that far exceeded expectations after Pfizer and its partner BioNTech.
Recently, the data from Moderna's trial involving 30,000 volunteers also showed the vaccine prevented cases of severe COVID-19, a question that remains with the Pfizer vaccine. Of the 95 cases in Moderna's trial, 11 were severe and all 11 occurred among volunteers who got the placebo.
Moderna, part of the US government's Operation Warp Speed program, expects to produce about 20 million doses for the US this year, millions of which the company has already made and is ready to ship if it gets FDA authorization.
More promising news today! This a.m. we learned that #Moderna's vaccine is 94% percent effective. From their early results of 30K people - 90 people in the placebo group developed Covid-19, 11 of them severely ill. In the vaccine group, only 5 became ill. (1/3) pic.twitter.com/EBQKAkbQsV— Dr. Sanjay Gupta (@drsanjaygupta) November 16, 2020
Moderna hopes to produce between 500 million and 1 billion doses in 2021, split between its US and international manufacturing sites, depending in part on demand. Unlike Pfizer's vaccine, Moderna's shot can be stored at normal fridge temperatures, which should make it easier to distribute, a critical factor as COVID-19 cases are soaring, hitting new records in the US and pushing some European countries back into lockdowns.
"We are going to have a vaccine that can stop COVID-19," Moderna President Stephen Hoge was quoted as saying by Reuters.